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Highlights 
 
 The potential for cardio-, neuro- and chondro-toxicity of intra-articular 
administration of lidocaine plus adrenaline was evaluated in dogs undergoing 
arthroscopy 
 The treatment was not found to cause adverse effects on the cardiovascular 
system.  
 The plasma concentrations of lidocaine did not reach neurotoxic 
concentrations.  
 Toxic effects of lidocaine on chondrocytes appeared to be reduced by 
adrenaline. 
Abstract 
The aim of this study was to evaluate the safety of intra-articular (IA) lidocaine 
plus adrenaline for improving peri-operative analgesia in anaesthetised dogs 
undergoing arthroscopy of the elbow. A solution of lidocaine (L) 1.98% plus 
adrenaline 1:100.000 was administered via the IA route and its safety evaluated in 
terms of cardio- neuro- and chondro-toxicity.  
 
No bradycardia or hypotension was recorded from induction to the last 
observational time point. Signs of toxicity of the nervous system could have been 
masked by the general anaesthesia but lidocaine concentrations detected in the blood 
were lower than those thought to be capable of producing toxicity. The assessment of 
in vitro chondrotoxicity showed a dose- and time-dependent effect of lidocaine on the 
viability of articular cells. Adrenaline appeared to reduce the chondrotoxicity of 1% 
lidocaine, following an exposure of up to 30 min.  
 
Keywords: Chondrotoxicity, Dog, Intra-articular administration, Lidocaine, 
Pharmacokinetics, Systemic toxicity. 
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Introduction 
Arthroscopic surgery plays an important role in the treatment of various joint 
diseases in dogs (Miller and Beale, 2008; Bergenhuyzen et al., 2010) and the 
increasing use of the technique has highlighted the need to improve the quality of 
analgesia in the perioperative period. In humans undergoing arthroscopy, the relief of 
pain using intra-articular (IA) administration of 2-agonists, opioids and local 
anaesthetics has been highly successful (Joshi et al., 2000; Elhakim et al., 1999). In 
particular, there are reports in the literature that effective analgesia follows an IA 
administration of lidocaine (Dahl et al., 1990; Arai et al., 2005). 
 
Lidocaine is a local anaesthetic easily adsorbed from the injection site, due to its 
chemical structure, has vasodilatory properties, and a pKa similar to the physiological 
pH (Schulman and Strichartz, 2012). Its absorption into the systemic circulation may 
cause cardiovascular and neurological toxic effects depending on the peak 
concentrations (Schulman and Strichartz, 2012). After IA administration of lidocaine 
2%, Di Salvo et al. (2014) observed no signs of toxicity as regards the cardiovascular 
and nervous system but treated dogs were under anaesthesia, which could have 
masked the possible neurotoxic effects. These authors observed a rapid absorption of 
lidocaine from the joint and, in some dogs, the peak drug concentrations were higher 
than those considered by Lemo et al. (2007) to be responsible for neurotoxic effects in 
dogs (2.7 µg/mL). The addition of a vasoconstrictor such as adrenaline to a local 
anaesthetic reduces the local perfusion and generally decreases the absorption of the 
anaesthetic and the likelihood of reaching potentially toxic blood concentrations (Van 
Vynck et al., 2010).  
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To the best of our knowledge, no studies on the safety of the IA administration 
of lidocaine plus adrenaline have been carried out during arthroscopic surgery in 
dogs. The purpose of this research was therefore to evaluate the absorption rate of 
lidocaine into the bloodstream after IA administration of a solution of lidocaine plus 
adrenaline in dogs undergoing arthroscopic surgery, in order to assess whether plasma 
concentrations potentially responsible for systemic toxicity would be reached. 
Moreover, since the use of local anaesthetics in humans by means of IA infusion 
pumps has been accompanied by severe cases of chondrolysis (Noyes et al., 2012) 
and we are unaware of any studies on the effect of lidocaine on the cells of canine 
cartilage, the possible toxic effects of lidocaine and lidocaine plus adrenaline on 
chondrocytes were also examined.  
 
Material and methods 
The study was approved by the Bioethical Committee of the University of 
Perugia (number 2012-039; 5 October 2012), and the owners, who had all been 
appropriately informed about the aims and modalities of the study, provided their 
written consent.  
 
Treatments and clinical evaluations of animals 
Twelve dogs admitted to the Veterinary Teaching Hospital of the University of 
Perugia for an elbow arthroscopic surgery were considered as eligible subjects for the 
study. All animals were healthy and classified as ASA I or II. The degree of 
inflammation was established by clinical and radiographic orthopaedic assessment, 
and a scoring scale from 1 to 4 (1 = low; 2 = low/moderate; 3 = moderate/high; 4 = 
severe) was applied to determine the severity of the joint disease. Dogs with 
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significant capsular swelling related to severe and extensive synovitis (degree 4) were 
not included in this study. The weight, age and degree of joint inflammation of the 
recruited animals are summarised in Table 1. 
 
A fresh solution of lidocaine plus adrenaline was prepared by adding 200 µL of 
a solution containing adrenaline (1 mg/mL) (Adrenalina Monico Spa) to 19.8 mL of 
2% lidocaine (Lidocaine Hydrochloride, SALF.). The final solution contained 1.98% 
lidocaine plus 1:100,000 adrenaline (pH 7.0). 
 
As a pre-emptive analgesic treatment, dogs received 0.1 mg/kg of meloxicam 
for at least 3 days before surgery. Prior to arthroscopy, dogs were premedicated with 
10 μg/kg of acepromazine (Prequillan, Fatro) by the intramuscular route, then general 
anaesthesia was induced with 4-6 mg/kg of propofol (Proposure, Merial) and 
maintained by a mixture of isoflurane (Isoflo; Esteve Spa) and oxygen (50-100 
mL/kg/min). Subsequently, dogs were randomly assigned to one of the following two 
experimental groups. Group LA (six subjects) received the solution of lidocaine plus 
adrenaline, and Group S (six subjects) received saline 0.9%.  
 
In order to assure a sufficient joint distension (necessary to minimize the trauma 
during the establishment of the arthroscope portal), in both groups the solutions were 
injected until the surgeon perceived a counter pressure on the plunger of the syringe. 
Thus, different volumes of the lidocaine-adrenaline solution and variable doses of 
lidocaine were injected in each joint. A volumetric limit was established at 10 mg/kg 
of lidocaine, which is the maximum therapeutic dose considered safe for regional and 
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local anaesthesia (Lemo et al., 2007). Table 1 summarises the injected volumes and 
the total doses of lidocaine administered to each dog.  
 
The arthroscopic procedure began 15 min after the injection and the joint was 
continuously flushed with Ringer lactate throughout the procedure. Immediately after 
the induction of anaesthesia, and up to recovery,  clinical parameters, namely, heart 
rate (HR), electrocardiogram (ECG), respiratory rate (RR), non-invasive systolic 
(SAP), diastolic (DAP) and mean arterial blood pressure (MAP), haemoglobin oxygen 
saturation, end-tidal carbon dioxide partial pressure, isoflurane exhaled concentration 
and rectal temperature (T°) were continuously monitored by a Multi-Parameter 
Monitor (HB100; Foschi).  
 
If an increase in HR, blood pressure or RR (>20% compared with baseline) was 
observed, one or more intravenous (IV) boluses of sufentanil (0.1 μg/kg, Sufentanil-
hameln, Hospira) were administered as rescue analgesia. The value recorded at the 
steady state of anaesthesia just before surgical procedures was used as the baseline 
measurement. To assure an adequate postoperative analgesia, 0.1 mg/kg of 
meloxicam (Metacam, Boehringer Ingelheim) was administered subcutaneously at the 
end of anaesthesia. 
 
At predetermined time-points during the post-surgical period, up to discharge, 
ECG, HR, RR, SAP, DAP, MAP and T° were monitored and dogs were evaluated for 
the presence of pain by mean of the numeric rating scale of Heyller and Gaynor 
(1998), slightly modified. If deemed necessary, 10 g/kg of buprenorphine were 
administered IV as rescue analgesia. 
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 Blood sampling 
At scheduled time points (0,  before; then 5, 10, 15, 30, 60, 90, 120, 180, 240 
and 360 min after  the IA administration of lidocaine plus adrenaline), blood samples 
were taken from the dogs of the LA group in order to determine the serum 
concentrations of lidocaine and its active metabolite monoethylglycinexylidide 
(MEGX).  
 
Analytical determination of lidocaine and MEGX 
Stock solutions (1 mg/mL) of lidocaine hydrochloride monohydrate (Dr 
Ehrenstorfer), MEGX (Sigma Aldrich) and lidocaine HCl d10 (internal standard, 
CDN Isotopes) were prepared in methanol and stored at -20 °C.  
 
Serum samples (100 µL) were added to 100 µL of internal standard and 800 µL 
of acetonitrile, vortexed and then centrifuged at 18,000 g for 5 min. Organic layers 
(100 µL) were diluted with 400 µL of acetonitrile and 10 µL were injected in the LC-
system. Quantitative analyses were conducted by means of a triple quadrupole mass 
spectrometer (TSQ Quantum Ultra, Thermo Fisher) equipped with a LC- system 
(Finnigan Surveyor LC pump, Thermo Fisher) via electrospray ionization (ESI) 
interface. The chromatographic analytical column was a BetaBasic-18 (150 mm  2.1 
mm, 5 µm, Thermo Electron Corporation). The separation was performed in gradient 
mode, using as mobile phases water and acetonitrile, both containing 0.1% (V/V) 
formic acid; the flow rate was 0.3 mL/min. The ESI source operated in positive ion 
mode. The parameters were as follows: spray voltage 3.5 kV and capillary 
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temperature 270 °C. The concentration of lidocaine or MEGX was determined by the 
internal standard method.  
 
In vitro evaluation of chondrotoxicity  
Canine chondrocytes were isolated from the cartilage harvested from the knee 
joints of a dog which had been euthanased for reasons unrelated to the present study. 
Primary cultures of canine chondrocytes were prepared and used to assess the cell 
viability following exposure to different concentrations of lidocaine alone at 0.5, 1 
and 1.98% (L) and lidocaine (same concentrations) plus adrenaline 1:100,000 (L+A). 
In a pilot study, the effects of chondrocyte exposure to adrenaline alone (10 µg/mL) 
were also tested and no significant reduction in cell viability was observed (data not 
shown). 
 
Cartilage slices were rinsed in Dulbecco's phosphate-buffered saline (DPBS), 
minced and digested primarily with 0.25% trypsin for 10 min at 37 °C and 
subsequently with 2 mg/mL collagenase type IA (Sigma-Aldrich) at 37 °C for 10/12 
h. The cells were cultured in a Dulbecco's Modified Eagle's Medium supplemented 
with 10% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 µg/mL) in 
5% CO2 at 37 °C in a humidified atmosphere. Cell viability was assessed by 
measuring the conversion of tetrazolium salt (WST-8) to a water-soluble formazan 
dye, using a cell counting kit-8 (CCK-8; Dojindo) according to the manufacturer's 
instructions.  
 
Cells were exposed for 10, 15, 30 and 60 min to L and L+A at the above 
reported concentrations. DPBS was used as a solvent to prepare dilution and as a 
Page 8 of 23
control medium. The effect of drugs on cell viability was expressed as the WTS-8 
percentage reduction in treated cells compared to the controls, assuming the 
absorbance of control cells was 100% (A(treated cells)/A(control) × 100). Data were obtained 
from four independent experiments, which were performed in triplicate and expressed 
as the means ± standard deviation (SD).  
 
Statistics and pharmacokinetic analysis 
The homogeneity of the groups as regards age, sex, weight and degree of lesion 
was evaluated by the Mann-Whitney test, whereas the correlation between the 
maximum serum concentrations and the volume of the injected solution, the dose and 
the degree of lesion was performed by Spearman's rank correlation. The statistical 
significance of changes in chondrocyte viability was determined by a one-way 
analysis of variance (ANOVA), followed by Bonferroni's post hoc test. For all tests a 
P value <0.05 was considered to be significant. All the statistical analyses were 
performed by the R software
1
 program. 
 
Pharmacokinetic parameters were obtained from concentration vs. time curves, 
using the WinNonLin Prof 6.1 software (Pharsight Corporation), which allowed 
compartmental and non-compartmental analyses of the data. The Minimum Akaike 
Information Criterion Estimation test (MAICE; Yamaoka et al. 1978) was used to 
choose the model best fitting the data. All data points were weighted by the inverse 
square of the fitted value. The serum lidocaine curve was described not only by a 
standard mono-compartment model, but also by a non-compartmental analysis 
                                                     
1
 See: R Development Core Team (2007). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-
project.org  (accessed 3 September 2015).  
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(NCA), whereas the kinetics of MEGX was determined only by NCA (Gibaldi and 
Perrier 1982). The metabolic ratio of lidocaine to MEGX was obtained by dividing 
the area under the curve (AUC) of MEGX by the AUC of lidocaine. 
 
Results 
Homogeneity of experimental group  
No statistical difference was observed between the control and the treated group 
as regards age, sex, weight and degree of the lesion (P>0.05). 
 
Clinical data 
No bradypnoea (reduction of 20% in RR compared to the baseline value), 
bradycardia (reduction of HR < 60 beats/min), hypotension (MAP < 60 mm Hg) or 
modifications in ECG were observed during the entire procedure, either in the LA or 
the S group.  No neurological signs, such as muscle tremors, excitation, convulsions 
or depression of the CNS, were reported during or after recovery from general 
anaesthesia. Three dogs in the L group and five in the S group received sufentanil as 
rescue analgesia (Table 1). 
 
Pharmacokinetic profile of lidocaine and MEGX 
Calibration curves obtained by spiking blank serum samples showed good 
linearity, as attested by the correlation coefficients (R
2
 >0.999). Detection (LOD) and 
quantification (LOQ) limits were equal to 5 and 10 ng/mL for lidocaine and 10 and 20 
ng/mL for MEGX, respectively. At validation levels  LOQ, the coefficients of 
variation (CV%) were always < 11% and accuracy ranged between 85% and 105% 
for lidocaine and between 98% and 109% for MEGX. 
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 Five minutes after the lidocaine injection, the blood concentrations of the local 
anaesthetic ranged from 0.013 to 0.980 µg/mL. The maximum serum concentration 
(Cmax) was between 0.188 and 2.188 µg/mL (mean ± SD 1.27 ± 0.81 µg/mL), and the 
mean Tmax was reached at 70.0 ± 84.14 min. In four subjects the serum peak was 
reached at 30 min after the lidocaine administration and at 60 min and 240 min in the 
remaining two dogs. The lidocaine active metabolite (MEGX) was detected in the 
systemic circulation at 5 min from the administration of lidocaine in one dog, and at 
60 min in all other subjects. The Cmax for MEGX was equal to 0.21 ± 0.16 µg/mL 
(range: 0.023-0.408 µg/mL) and was reached at a Tmax of 130 ± 67.53 min after 
administration. After reaching Cmax in the blood, both lidocaine and MEGX decreased 
in a parallel manner, achieving a concentration of 0.283 ± 0.199 and 0.064 ± 0.019 
µg/mL, respectively, at 360 min (Fig. 1).  Table 2 reports the main pharmacokinetic 
parameters for lidocaine and MEGX. The metabolic ratio ranged between 0.08 and 
0.28. The correlation coefficient between Cmax and the dose, the severity of the lesion 
and the volume of injected solution was not significant (P ≥0.29). 
 
Chondrotoxicity 
Fig. 2 represents the percentage of viability of the chondrocytes after exposure 
to different concentrations of L and L+A for different times of exposure. The 
exposure to 1%, 1.98% L and 1.98% L+A induced a statistically significant reduction 
in cell viability with respect to controls at all times tested (P ≤0.036). A statistically 
significant cytotoxicity with respect to controls was caused by 1% L+A only after 
exposure for 60 min (P = 0.001).  
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The exposure of chondrocytes to 0.5% L or L+A produced no statistically 
significant differences in cell viability with respect to controls after any exposure 
time. However, it was noted that the percentage cell viability after exposure of 
chondrocytes to 0.5% L and L+A was 93.65 ± 5.98 and 101.93 ± 7.69 at 10 min, 
89.86 ± 3.81 and 100.77 ± 4.54 at 15 min, 86.19 ± 8.50 and 99.39 ± 6.14 at 30 min, 
and 80.37 ±5.65 and 92.31 ±2.35 at 60 min, respectively, indicating a marked 
improvement in cell viability in the presence of adrenaline. 
 
Discussion  
In veterinary medicine, the IA administration of local anaesthetic is a common 
practice both for diagnostic purposes and for relieving post-surgical pain (Gurney et 
al., 2012; Sammarco et al., 1996, Van Vynckt et al., 2012a, 2012b).  
 
In this study, the IA administration of a solution of 1.98% lidocaine plus 
1:100,000 adrenaline (prepared in the clinic) was evaluated in dogs undergoing 
arthroscopy in order to assess the potential local and systemic toxicity of the local 
anaesthetic. The solution of lidocaine plus adrenaline was prepared extemporaneously 
because the commercially available formulations have a low pH resulting in a smaller 
percentage of the undissociated form of lidocaine and therefore a delayed onset of 
action (Van Vynckt et al., 2010). 
 
Different volumes of the lidocaine plus adrenaline solution were injected into 
each dog’s joint. This treatment option was preferred to the use of a fixed volume, as 
the joint capacity was dependent on the degree of inflammation. This however 
represents a major limitation of the study, as different volumes administered into the 
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joints with various degrees of inflammation resulted in a large variability both in 
lidocaine blood concentrations vs. time and in pharmacokinetic parameters. We must 
emphasise that the pharmacokinetic values obtained in this study should only be used 
for comparative purposes and not as absolute values. 
 
The high variability of the obtained lidocaine Cmax (between 0.188 and 2.188 
µg/mL) was not statistically correlated to the administered dose, the injected solution 
volume or the severity of the lesions (P> 0.05). All these variables together could 
have accounted for such high variability. Moreover, the different degrees of 
vascularization in the diseased joint and/or the different metabolic capacities of dogs 
may also have contributed to such variability. The AUC ratio for MEGX/Lidocaine 
calculated for each subject ranged from 0.08 to 0.28, indicating a large amount of 
variability between individuals in the production of the active metabolite. Other 
authors have previously observed significant variation in the capacity of individuals to 
metabolise IV administered lidocaine, including in dogs and humans (Conti et al., 
2004; Neumann et al., 2011). It should also be noted that our study was conducted 
with a limited number of animals during a surgical practice and not under 
experimental conditions. Future studies with a larger number of more closely matched 
animals may reduce this variability.  
 
The mean lidocaine Cmax reached in this study was equal to 1.27 ± 0.81 µg/mL 
(mean ± SD). This value is approximately half of that observed in a similar study 
(2.18 ± 0.91 µg/mL; Di Salvo et al., 2014), where 2% lidocaine was administered by 
the IA route without the addition of adrenaline. Narchi et al. (1992) also observed a 
reduction in the Cmax to approximately half after the intraperitoneal administration of 
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a solution of 0.5% lidocaine plus adrenaline (1:800,000 and 1:320,000), compared to 
the values obtained after the administration of lidocaine alone. Conversely, Calvo et 
al. (1995) noticed no difference in Cmax values following the administration of 
lidocaine or lidocaine plus adrenaline in the interpleural space.  
 
In this study, after administration of lidocaine, the Tmax was greater than that 
observed by Di Salvo et al. (2014) (70 min vs. 28.75 min). This delay agrees with data 
obtained by Narchi et al. (1992) and Calvo et al. (1995). Similarly, the time of the 
appearance of the MEGX was also delayed compared to that observed by Di Salvo et 
al. (2014) (130 min vs. 60 min). Moreover, the mean residence time (MRT) was 
prolonged if compared with previous results obtained using lidocaine alone (MRT 0-
last: 155.43 min vs. 91 min for lidocaine and 163.21 min vs. 115.40 min for MEGX). 
 
Conversely, the mean AUC of lidocaine was comparable to that obtained in the 
previous study (224.76 µg.min/mL vs. 228.64 µg.min/mL). As the administered doses 
in the two studies were similar (6.40 - 9.43 mg/kg, vs. 5.26-10 mg/kg), these data 
indicate that the addition of adrenaline to lidocaine did not reduce the total amount of 
the drug which reached the systemic circulation, but only slowed its absorption. 
 
Signs of cardiotoxicity, such as bradycardia, transient lengthening of AV node 
conduction, a decrease in myocardial contractility and vasodilation, have been 
described by Bruelle et al. (1996) following the administration of lidocaine (16 
mg/kg, IV) in dogs under general anaesthesia. In our study, no modifications in ECG, 
hypotension or bradycardia were observed during the entire procedure, demonstrating 
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a reliable safety margin of IA lidocaine towards the cardiovascular system at the 
applied dose rates.  
 
Muscle tremors are considered the first sign of lidocaine toxicity in dogs 
(Skarda and Tranquilli, 2007). Lemo et al. (2007) noted this occurred when the 
lidocaine blood concentration reached 2.7 ± 1.1 µg/mL. Since in the present study any 
neurotoxicity of lidocaine would have been masked by general anaesthesia, the 
possibility that potentially neurotoxic blood concentrations might occur following IA 
administration of the solution of lidocaine plus adrenaline was investigated. The 
results showed that the maximum concentration of lidocaine reached was 2.188 
µg/mL, which was lower than that indicated by Lemo et al. (2007) as responsible for 
the appearance of neurotoxic effects. In the study conducted by Di Salvo et al. (2014) 
with lidocaine alone concentrations > 2.7 ± 1.1 µg/mL were reached. As that study 
was conducted using the same protocol as the present study (the only difference was 
the presence or the absence of adrenaline) it is possible to postulate that the addition 
of adrenaline, which slows the absorption of lidocaine, does not allow blood 
concentrations high enough to cause neurological adverse effects. 
 
In the in vitro evaluation of local toxicity, lidocaine appears to be chondrotoxic 
in a time- and concentration-dependent manner. These results agree with the 
observations of Karpie and Chu (2007) who tested lidocaine chondrotoxicity on 
bovine cells. However, after exposure to lidocaine plus adrenaline, the reduction in 
chondrocyte viability was less pronounced than after lidocaine alone (Fig. 2). That is 
particularly evident after cells exposure to 1% L or L+A: in the first case viability was 
statistically reduced with respect to controls at all observation times, whereas in the 
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second case the viability was significantly reduced only 1 h after exposure. Similar 
results were obtained by Jacobs et al., (2011) following the exposure of human 
chondrocytes to 1% L and 1% L + A. These authors speculated that adrenaline may 
exert a protective effect on chondrocytes but the data presented in the literature are 
equivocal. Dragoo et al. (2008) reported an increased toxicity of local anaesthetics 
plus adrenaline, but in that study cells were exposed to the mixture for more than 24 
h. Moreover, in a following study, Dragoo et al. (2010) hypothesized that increased 
cellular necrosis may have been associated with the low pH and preservative 
substances contained in the local anaesthetic plus adrenaline solution. The use of a 
solution made up in-house in the present study may have further contributed to the 
different results obtained.  Consistent with the results of the study by Lo et al. (2009), 
no effect of adrenaline alone on chondrocyte viability was observed.  
 
The observations carried out following in vitro studies do not necessarily reflect 
what occurs in vivo. The effects of lidocaine on chondrocytes could be reduced by the 
dilution of the anaesthetic, its absorption into the bloodstream and/or the washing 
during the arthroscopic procedure. Conversely, the delayed absorption of lidocaine in 
the presence of adrenaline could prolong the contact of the local anaesthetic with the 
cells and thus lead to a higher potential for chondrotoxicity. In vivo studies aimed at 
further elucidating the adverse effects of lidocaine on articular structures are 
warranted. 
 
Conclusions 
The IA administration of 1.98% lidocaine plus adrenaline in dogs which have 
undergone arthroscopic surgery did not appear to produce any adverse effects on the 
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cardiovascular system. Following the absorption of the anaesthetic, the peak plasma 
concentrations did not reach those considered to be responsible for side effects at the 
central nervous system level. Although lidocaine plus adrenaline was found to have a 
lesser impact on cell viability compared with lidocaine alone, some chondrotoxicity 
was demonstrated in vitro.  
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Figure legend 
 
Fig. 1. Semi logarithm plot of average lidocaine (solid line, triangle) (--) and 
MEGX (dotted line, square) (--) concentrations vs. time after lidocaine IA 
administration in dog (n= 6). Bars represent the standard deviation. 
 
Fig. 2. Cell viability % (mean + standard deviation) after exposure to different 
concentrations of lidocaine and lidocaine plus adrenaline for 10, 15, 30 and 60 min 
compared with saline (CTR). 
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Table 1. Age, weights, sex, articular pathology, degree of inflammation of recruited 
animals and pharmacological treatments. 
Age 
(months) 
Weight 
(kg) 
 
Sex 
 
Disease 
Score 
attributed 
to lesion 
 
Treatment 
mL 
admin. 
Dose 
(mg/kg) 
n. 
Sufentanil 
boluses * 
10 31.5 M FCP 3 Lidocaine + adrenaline 15 9,43 0 
84 37.1 M DJD 1 Lidocaine + adrenaline 12 6,40 3 
24 56.4 M ED 2 Lidocaine + adrenaline 20 7,02 1 
12 31.7 M FCP 2 Lidocaine + adrenaline 12 7,50 0 
9 29.7 F FCP 2 Lidocaine + adrenaline 13 8,67 0 
18 28.7 M MCD 2 Lidocaine + adrenaline 12 8,28 1 
6 27 M OCD 2 saline 15  1 + CRI 
11 33 M OCD 1 saline 15  3 
12 38 F FCP 3 saline 18  0 
24 57 M OCD 2 saline 20  1 
84 37.5 M FCP 1 saline 9  4 
30 34 M FCP 3 saline 10  1 
 
* 0,1 µg/kg as rescue analgesia 
FCP, Fragmented coronoid process; DJD, Degenerative joint disease; ED, Elbow dysplasia; 
MCD, Medial Compartment Disease; OCD, Osteochondritis dissecans; 1,low; 2, moderate; 3, 
high; F, Female; M, Male; CRI, Continuous rate infusion(0.5 µg/kg).  
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Table 2. Pharmacokinetic parameters of lidocaine and MEGX obtained by mono-compartmental 
and non-compartmental model following lidocaine IA administration in dog (n=6). 
Parameter Unit Mean SD. 
Lidocaine 
Mono-compartmental analyses 
AUC µg.min/mL 418.83 348.80 
t½ abs min 22.94 15.58 
t½ elim min 158.29* 88.42* 
Tmax min 78.74 44.59 
Cmax µg/mL 1.05 0.73 
Non-compartmental analyses 
t½z min 149.18* 105.84* 
Tmax obs min 70.00 84.14 
Cmax obs µg/mL 1.27 0.81 
AUC 0-last µg.min/mL 224.76 132.90 
MRT 0-last min 155.43 23.93 
MEGX 
t z min 118.25* 56.02* 
Tmax obs min 130.00 67.53 
Cmax obs µg/mL 0.21 0.16 
AUC 0-last µg.min/mL 44.89 30.55 
MRT 0-last min 163.21 18.82 
*
 harmonic mean ± pseudo SE; AUC: area under serum 
concentration-time curve; t½ abs: absorption half-life; t½elim: 
elimination half-time; MRT0-last: mean residence time; t½z: 
terminal half-time;  Tmax = time of peak concentration; Tmax obs = 
Time of maximum concentration observed Cmax = Maximum 
concentration; Cmax obs = Maximum concentration observed; . 
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